The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high ...

Ministers want to examine the impact of the weight loss drug tirzepatide on people’s health outcomes and employment status. Elisabeth Mahase looks at how the study will work A new partnership between ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.

US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...